Stay updated with breaking news from ஷில்பா சிங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Super Dancer - Chapter 4 judge Anurag Basu: I don’t think I can ever judge a reality show with adults + We serve personalized stories based on the selected cityOK Hello, Subscribe Please enter valid email. Thank you for subscribing!Your subscription is confirmed for latest news across Entertainment, Television and Lifestyle newsletters. Super Dancer - Chapter 4 judge Anurag Basu: I don Super Dancer - Chapter 4 judge Anurag Basu: I don’t think I can ever judge a reality show with adults Comments () Help us delete comments that do not follow these guidelines by marking them offensive. Let s work together to keep the conversation civil. ....
Three products exempted from Import Alert Shilpa Medicare has received an Import Alert 66-40 on 17 February 2021, pursuant to the USFDA inspection of the Unit 4, Jadcherla, Telangana facility from 13 February to 20 February and 24 February to 25 February 2020. The company announced that three products have been exempted from the Import Alert - Azacitidine for Injection, Cyclophosphamide Capsules and Erlotinib Tablets Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader, Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult ....
Shilpa Medicare fell 1.25% to Rs 424.30, extending losses for third day. The stock has declined 1.6% in three sessions from its recent closing high of Rs 431 on 10 February 2021. In the past six months, the stock has declined by 31.99% while the benchmark Sensex has added 37.61% during the same period. In a BSE filing made during market hours today, Shilpa Medicare announced the launch of Sunitinib capsules, under the brand name SUNISHIL in India. The Sunitinib capsules has been launched in three strengths of 12.5 mg, 25 mg and 50 mg Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. The drug is indicated for the treatment of G.I. Stromal tumor after disease progression on or intolerance to Imatinib mesylate, advanced Renal Cell Carcinoma, and for the treatment of Unresectable or Metastatic Welldifferentiated Pancreatic Neuroendocrine Tumors with Disease Progression in adults. ....